Mark Christianson Sells 30,000 Shares of NeuroOne Medical Technologies (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Director Mark Christianson sold 30,000 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $0.74, for a total value of $22,200.00. Following the transaction, the director directly owned 231,238 shares in the company, valued at approximately $171,116.12. This represents a 11.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NeuroOne Medical Technologies Trading Down 0.6%

NeuroOne Medical Technologies stock opened at $0.89 on Thursday. The stock has a 50 day moving average of $0.79 and a two-hundred day moving average of $0.75. NeuroOne Medical Technologies Corporation has a twelve month low of $0.40 and a twelve month high of $1.39. The stock has a market capitalization of $44.40 million, a price-to-earnings ratio of -5.92 and a beta of 0.68.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Thursday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. The business had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.82 million. NeuroOne Medical Technologies had a negative return on equity of 163.49% and a negative net margin of 55.44%. NeuroOne Medical Technologies has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On NeuroOne Medical Technologies

A number of institutional investors and hedge funds have recently modified their holdings of NMTC. Warberg Asset Management LLC purchased a new position in NeuroOne Medical Technologies in the 2nd quarter valued at approximately $27,000. Jane Street Group LLC acquired a new stake in NeuroOne Medical Technologies in the fourth quarter valued at $33,000. XTX Topco Ltd acquired a new stake in NeuroOne Medical Technologies in the second quarter valued at $51,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of NeuroOne Medical Technologies in the first quarter valued at $69,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of NeuroOne Medical Technologies during the 1st quarter worth $84,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Maxim Group assumed coverage on NeuroOne Medical Technologies in a report on Tuesday. They issued a “buy” rating and a $3.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, NeuroOne Medical Technologies currently has a consensus rating of “Buy” and an average price target of $2.23.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.